Filtered By:
Condition: Atrial Fibrillation
Procedure: Dialysis
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 370 results found since Jan 2013.
Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation
Conclusions Among older adults with AF, warfarin therapy initiation was associated with a significantly lower 1-year risk for the composite outcome across all strata of kidney function. The risk for major bleeding associated with warfarin use was increased only among those with eGFRs of 60 to 89mL/min/1.73m2.
Source: American Journal of Kidney Diseases - December 18, 2016 Category: Urology & Nephrology Source Type: research
Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease.
CONCLUSION: Despite the unclear benefit and increased bleeding risk of warfarin treatment in patients with ESRD, 1 in 8 older adults undergoing dialysis with incident AF in the US who had high risk of bleeding used warfarin. Changes to warfarin therapy due to discontinuation were common after initiation.
PMID: 28120282 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - January 23, 2017 Category: Urology & Nephrology Authors: Tan J, Bae S, Segal JB, Zhu J, Segev DL, Alexander GC, McAdams-DeMarco M Tags: J Nephrol Source Type: research
Association of warfarin with congestive heart failure and peripheral artery occlusive disease in hemodialysis patients with atrial fibrillation
Conclusion Warfarin may be associated with vascular calcification, increasing the risks of congestive heart failure and peripheral artery occlusive disease among HD-AF patients.
Source: Journal of the Chinese Medical Association - February 14, 2017 Category: Journals (General) Source Type: research
End ‐stage renal disease and severe aortic stenosis: Does valve replacement improve one‐year outcomes?
ConclusionsPatients with ESRD and severe AS have a similar and higher survival with TAVR or SAVR when compared to BAV at 1‐year. These results may influence patient care decisions favoring valve replacement in AS patients with ESRD. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - February 16, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Jose F. Condado, Aneel Maini, Bradley Leshnower, Vinod Thourani, Jessica Forcillo, Chandan Devireddy, Kreton Mavromatis, Eric L. Sarin, James Stewart, Robert Guyton, Amy Simone, Patricia Keegan, Stamatios Lerakis, Peter C. Block, Vasilis Babaliaros Tags: Valvular and Structural Heart Diseases Source Type: research
Atrial Fibrillation and end-stage renal failure patients on dialysis: balancing the risks and benefits of stroke prevention
Publication date: Available online 28 February 2017 Source:Canadian Journal of Cardiology Author(s): Christos Voukalis, Gregory YH. Lip
Source: Canadian Journal of Cardiology - February 27, 2017 Category: Cardiology Source Type: research
Antithrombotic therapy in end ‐stage renal disease
Abstract
The delicate balance of risk vs. benefit of using antiplatelet and antithrombotic agents in the general population is well established. The decision to use these agents in the end stage renal disease (ESRD) population remains complex and difficult. The concomitant association of a prothombotic state with high risk of bleeding in the ESRD population requires individualization and careful clinical judgment before implementing such therapy. There remains a paucity of clinical trials and lack of substantial evidence in literature for safe and effective use of antithrombotic drugs in patients with advanced chronic kidn...
Source: Hemodialysis International - April 1, 2017 Category: Hematology Authors: Svetha Chunduri, Jon E. Folstad, Tushar J. Vachharajani Tags: Review Article Source Type: research
Atrial Fibrillation and End Stage Renal Failure in Patients Receiving Dialysis: Balancing the Risks and Benefits of Stroke Prevention
Publication date: June 2017 Source:Canadian Journal of Cardiology, Volume 33, Issue 6 Author(s): Christos Voukalis, Gregory Y.H. Lip
Source: Canadian Journal of Cardiology - May 24, 2017 Category: Cardiology Source Type: research
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients
It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hou...
Source: Journal of the American Society of Nephrology : JASN - June 30, 2017 Category: Urology & Nephrology Authors: Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., Lipman, M. L. Tags: Clinical Research Source Type: research
Preoperative Assessment of Endothelial Function for Prediction of Adverse Events After Cardiovascular Surgery.
CONCLUSIONS: Preoperative endothelial dysfunction assessed by RHI was associated with postoperative AEs in patients with cardiovascular surgery.
PMID: 28768922 [PubMed - as supplied by publisher]
Source: Circulation Journal - August 3, 2017 Category: Cardiology Authors: Saito Y, Kitahara H, Matsumiya G, Kobayashi Y Tags: Circ J Source Type: research
Straight deep hypothermic circulatory arrest for aortic arch surgery: Going the way of the dinosaurs?
In this issue of the Journal, Damberg and colleagues1 report their experience with straight deep hypothermic circulatory arrest (DHCA) as the sole means of brain protection during operations on the aortic arch in 613 consecutive patients, focusing on late outcomes.1 The independent variables associated with increased 1-year mortality were acute type A aortic dissection, reoperative status, and the presence of descending thoracic aortic pathology. The independent variables associated with increased mortality beyond 1 year were increased age, postoperative complications (stroke, dialysis, pulmonary complications), and post...
Source: The Journal of Thoracic and Cardiovascular Surgery - August 28, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Nicholas T. Kouchoukos Tags: Editorial commentary Source Type: research
Impact of elevated glycosylated hemoglobin on hospital outcome and 1 year survival of primary isolated coronary artery bypass grafting patients
Conclusions This study showed that HbA1c is a good predictor of in-hospital morbidity. It worth devoting time and effort to decrease HbA1c level below 7% to decrease possible postoperative complications.
Source: The Egyptian Heart Journal - October 28, 2017 Category: Cardiology Source Type: research
Transcatheter or surgical aortic valve replacement in patients with advanced kidney disease: A propensity score –matched analysis
ConclusionsIn patients with advanced kidney disease, SAVR was associated with higher mortality and higher periprocedural complications, as compared with TAVR. Thus, benefits of TAVR could be extended in patients with advanced kidney disease who cannot undergo surgery.
Source: Clinical Cardiology - October 1, 2017 Category: Cardiology Authors: Rajkumar Doshi, Jay Shah, Vaibhav Patel, Varun Jauhar, Perwaiz Meraj Tags: CLINICAL INVESTIGATIONS Source Type: research
Intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation: A meta-analysis
Conclusion: ECMO support for LuTx showed better clinical outcomes compared to CPB.
Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Magouliotis, D., Svokos, A., Svokos, K., Olland, A., Massard, G., Tasiopoulou, V., Zacharoulis, D. Tags: Transplantation Source Type: research
‘Some doors are better left closed’: Using LAA occluders as an alternative to warfarin in very high-risk dialysed patients with atrial fibrillation
Since 2011, when the EMA approved the treatment with novel oral anticoagulants (NOACs) for primary prevention of cardio-embolic stroke in patients with atrial fibrillation (AF), a reasonable question repeatedly arose: “Will NOACs become the new standard of care in anticoagulation therapy?” [1]. While for many cathegories of patients the answer soon become positive [2], the sub-group of advanced chronic kidney disease (CKD) 5D stage (in dialysis) has never received a “yes” from either FDA or EMA (none of t hem allowing the use of NOACs in 5D CKD).
Source: International Journal of Cardiology - April 27, 2018 Category: Cardiology Authors: Alexandru Burlacu, Adrian Covic Tags: Editorial Source Type: research
Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.
CONCLUSION: The cardiological societies' recommendation that patients with atrial fibrillation should be given oral anticoagulant drugs applies to the majority of such patients who also have chronic kidney disease.
PMID: 29789105 [PubMed - in process]
Source: Deutsches Arzteblatt International - May 24, 2018 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
